MedTrace Logo

Effectiveness of Adding Remune to Your Current Anti-HIV Drug Combination

NCT00006153 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2008-07-30

No results posted yet for this study

Summary

The purpose of this study is to see if giving a vaccine (Remune) is effective in HIV-positive patients who are also taking anti-HIV therapy.

Regular treatment of HIV-positive patients with anti-HIV drugs slows the multiplication of the HIV virus in the body. A vaccine called Remune works to stop the virus infection by "boosting" the body's immune cell defense against the HIV virus before the virus enters cells. It also blocks the virus from entering the cells. This study will see whether Remune will improve the immune cell natural defense in patients who are also taking anti-HIV drugs.

Conditions

  • HIV Infections

Interventions

BIOLOGICAL

HIV-1 Immunogen

Sponsors & Collaborators

  • The Immune Response Corporation

    collaborator INDUSTRY

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • Eric Daar

  • Susan Little

  • Janis Giorgi

  • Rachel Schrier

Study Design

Purpose
TREATMENT
Masking
DOUBLE

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00006153 on ClinicalTrials.gov